Good time to buy for those who are in for the long haul, imo.
New CSO guidelines will now exclude manufacturers ability to supply directly to pharmacies, cutting out the CSO. While the new arrangements take effect from 2020, apparently some suppliers are going to move away from the model earlier. AstraZeneca are going to start transitioning away from Feb 2019.
My guess is the further drop in the share price might be related to those not prepared to hang around until 2020.
https://ajp.com.au/news/no-new-exclusive-direct-supply-after-2020/
New CSO guidelines scrap 'Direct Supply' from manufacturers
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SIG (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.78 |
Change
0.080(2.96%) |
Mkt cap ! $2.300B | |||
| Open | High | Low | Value | Volume |
| $2.74 | $2.93 | $2.74 | $37.80M | 13.25M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 167207 | $2.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.79 | 246261 | 9 |
View Market Depth
| Last trade - 16.10pm 28/11/2024 (20 minute delay) ? |
| SIG (ASX) Chart |
